GT Biopharma Inc GTBP 深 沪
等待开盘 05-18 09:30:00 美东时间
0.3939
-0.045
-10.25%
华盛通- 最 高0.4641
- 今 开0.4508
- 成交量 400.63万股
- 最 低 0.375
- 昨 收 0.4389
- 总市值 1403.17万
- 52周最高 3.85
- 市盈率 静 --
- 换手率 11.25%
- 52周最低 0.261
- 委 比 66.67%
- 总股本 3562.24万
- 历史最高 591.99
- 量 比 1.19
- 振 幅 20.30%
- 历史最低 0.261
- 每 手 1
- 风险率 0.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多GT Biopharma Q1 EPS $(0.11) Misses $(0.08) Estimate
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.08) by 37.5 percent. This is a 66.67 percent increase over losses of $(0.33) per share from the
05-15 20:19
GT Biopharma Reports First Quarter 2026 Financial Results
GT Biopharma announced its Q1 2026 financial results, highlighting $9 million in cash and ongoing Phase 1 trials for GTB-3650 and GTB-5550. GTB-3650 targets CD33-positive leukemias, with enrollment progressing through dose escalation cohorts. GTB-5550, the first subcutaneously administered TriKE, focuses on B7-H3-positive solid tumors, with enrollment ongoing across multiple tumor types. The company expects updates on both programs in H2 2026. GT...
05-15 12:00
EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types
GT Biopharma doses first patient in Phase 1 GTB-5550 trial targeting B7-H3-positive solid tumors with subcutaneous TriKE therapy.
05-14 20:16
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Alpha Compute (NASDAQ:ALP) shares increased by 71.3% to $0.46 during T...
05-14 20:05
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Intellia Therapeutics (NASDAQ:NTLA) stock rose 19.1% to $16.23 during ...
04-25 05:05
GT Biopharma to Participate in the 38th Annual Roth Conference
GT Biopharma, Inc. (NASDAQ: GTBP) announced that its Executive Chairman and CEO, Michael Breen, will participate in the 38th Annual Roth Conference on March 22-24, 2026, in Laguna Niguel, CA. The Company will present on March 24, 2026, at 1:30 PM PDT and will be available for one-on-one investor meetings. For more information, visit https://www.gtbiopharma.com. The Company focuses on immuno-oncology therapeutics using its proprietary TriKE® NK ce...
03-11 11:00
GT Biopharma reports FY results
GT Biopharma press release (GTBP): FY The Company reported a net loss of approximately $28.4 million for the year ended December 31, 2025, compared to $13.2 million for the prior year. The Company re...
03-03 03:42
GT Biopharma Q4 EPS $(4.84) Down From $(1.66) YoY
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(4.84) per share. This is a 191.57 percent decrease over losses of $(1.66) per share from the same period last year.
03-02 22:28
GT Biopharma Reported FY25 Net Loss Of $28.4M, Cash Balance Of ~$9M To Fund Operations Through The Fourth Quarter Of 2026
Year Ended December 31, 2025 Financial SummaryCash Position: The Company had cash and cash equivalents of approximately $7 million as of December 31, 2025, and an unaudited proforma cash balance as of January 31, 2026 of
03-02 20:24
GTBP FY 2025 net loss widens to USD 28.4 million on non-cash fair value charge
GTBP FY 2025 net loss widens to USD 28.4 million on non-cash fair value charge GT Biopharma reported FY 2025 results, ending the year with cash and cash equivalents of about USD 7 million and citing an unaudited proforma cash balance of about USD 9 million as of Jan. 31, 2026, which it expects to fu
03-02 20:02
